Characterization and Epigenetics of Post-Partum Preeclampsia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Marie-Louise Meng, MD
- Phone Number: 919-613-9054
- Email: marielouise.meng@duke.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10023
- Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Post partum pre-eclampsia
Matching based on:
- maternal age (years +/-3)
- BMI (+/-5 points)
- Ethnicity
- Mode of delivery
- Gestational age at delivery (+/7 days)
- Smoking status
Exclusion Criteria:
- Intrapartum pre-eclampsia
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
post partum pre-eclampsia
women with normal deliveries followed by post partum pre-eclampsia within 1 month of delivery.
|
database and epigenetic study
|
|
controls
women with normal deliveries and normal post part courses who match the post partum pre-eclampsia women in age, BMI, smoking status, gestational age and race/ethnicity.
|
database and epigenetic study
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
methylation signature on circulating monocytes
Time Frame: 1 week post delivery
|
1 week post delivery
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Marie-Louise Meng, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PRO00104636
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post Partum Pre-eclampsia
-
NCT01480544CompletedSepsis | Obstetric Labor Complications | Pre-eclampsia | Neonatal Mortality | Post-partum Hemorrhage
-
NCT02307201CompletedPost Partum Severe Preeclampsia
-
NCT07263490RecruitingPreterm Labor | Gestational Diabetes | Pre-eclampsia | Neonatal Morbidity | Pre-eclampsia or Eclampsia With Pre-existing Hypertension | Placental Abruption | ART | Neonatal Mortality | Pre-Eclampsia, Severe | Intrauterine Growth Restriction (IUGR)
-
NCT07646561Completed
-
NCT06452498Not yet recruitingPre-Eclampsia | HELLP Syndrome | Pre-eclampsia or Eclampsia With Pre-existing Hypertension | HELLP | Pre-Eclampsia; Complicating Pregnancy | Pre-Eclampsia Onset Less Than 37 Weeks | Pre-Eclampsia as Antepartum Condition | Pre-Eclampsia; Affecting Fetus | HELLP Syndrome Complicating Pregnancy
-
NCT06259240RecruitingPost Partum Women
-
NCT03353012CompletedBreastfeeding | Post Partum
-
NCT03118726CompletedPost Partum Contraception
-
NCT02147626CompletedHypertension | Cardiovascular Disease | Preeclampsia | Post-partum Weight Retention
Clinical Trials on no intervention
-
NCT06980844Not yet recruitingInterstitial Lung Disease
-
NCT02746445Completed
-
NCT05345054CompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social Behavior
-
NCT01923415CompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, Discoid
-
NCT06686342RecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in Vitro
-
NCT06134739RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | Ablation
-
NCT03305484CompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein Staining
-
NCT03385811UnknownIntention to Stay, Turnover Behavior